ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004
January 18, 2022 08:06 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Management to host the second webinar in ASLAN’s A4 series on Thursday, January 20, 2022, at 12:00pm ET MENLO PARK, Calif., and SINGAPORE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- ASLAN...
ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004
October 18, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET - First patient in global, 300-patient Phase 2b study of ASLAN004 on track for enrolment...
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology
October 14, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
September 27, 2021 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus...
ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield
September 21, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
August 04, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
July 13, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 07:30 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 - Phase 2b clinical trial for ASLAN004 expected to...
ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology
May 05, 2021 05:22 ET
|
ASLAN PHARMACEUTICALS LIMITED
- ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021 SINGAPORE, May 05, 2021 (GLOBE NEWSWIRE) --...